These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 8205528)

  • 61. Phase I evaluation of interleukin-2-transfected irradiated allogeneic melanoma for the treatment of metastatic melanoma: appendix 1: protocol.
    Das Gupta TK; Cohen EP; Richards JM
    Hum Gene Ther; 1997 Sep; 8(14):1701-14. PubMed ID: 9322873
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Identification of tumor antigens: strategies and perspectives].
    Jäger D; Zippelius A; Knuth A
    Praxis (Bern 1994); 2004 Sep; 93(39):1584-8. PubMed ID: 15500242
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy.
    van den Boorn JG; Picavet DI; van Swieten PF; van Veen HA; Konijnenberg D; van Veelen PA; van Capel T; Jong EC; Reits EA; Drijfhout JW; Bos JD; Melief CJ; Luiten RM
    J Invest Dermatol; 2011 Jun; 131(6):1240-51. PubMed ID: 21326294
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Human tumour antigens recognized by T-cells: perspectives for new cancer vaccines.
    Van den Eynde B; Gaugler B; van der Bruggen P; Coulie P; Brichard V; Boon T
    Biochem Soc Trans; 1995 Aug; 23(3):681-6. PubMed ID: 8566443
    [No Abstract]   [Full Text] [Related]  

  • 65. The Antigenicity of the Tumor Cell - Context Matters.
    Kristensen VN
    N Engl J Med; 2017 Feb; 376(5):491-493. PubMed ID: 28146670
    [No Abstract]   [Full Text] [Related]  

  • 66. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells.
    Robbins PF; Lu YC; El-Gamil M; Li YF; Gross C; Gartner J; Lin JC; Teer JK; Cliften P; Tycksen E; Samuels Y; Rosenberg SA
    Nat Med; 2013 Jun; 19(6):747-52. PubMed ID: 23644516
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Evolving role of tumor antigens for future melanoma therapies.
    Andrews MC; Woods K; Cebon J; Behren A
    Future Oncol; 2014 Jun; 10(8):1457-68. PubMed ID: 25052755
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes.
    Carretero R; Wang E; Rodriguez AI; Reinboth J; Ascierto ML; Engle AM; Liu H; Camacho FM; Marincola FM; Garrido F; Cabrera T
    Int J Cancer; 2012 Jul; 131(2):387-95. PubMed ID: 21964766
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The Waardenburg syndrome type 4 gene, SOX10, is a novel tumor-associated antigen identified in a patient with a dramatic response to immunotherapy.
    Khong HT; Rosenberg SA
    Cancer Res; 2002 Jun; 62(11):3020-3. PubMed ID: 12036907
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Proteomic scan for tyrosinase peptide antigenic pattern in vitiligo and melanoma: role of sequence similarity and HLA-DR1 affinity.
    Lucchese A; Willers J; Mittelman A; Kanduc D; Dummer R
    J Immunol; 2005 Nov; 175(10):7009-20. PubMed ID: 16272362
    [TBL] [Abstract][Full Text] [Related]  

  • 71. In situ detection of antigen-specific tumor-infiltrating lymphocytes using newly designed tetramers.
    Bras-Gonçalves R; Le Gal FA; Avril MF; Dalod M; Connan F; Chaboissier A; Choppin J; Guillet JG
    J Immunol Methods; 2003 Sep; 280(1-2):103-11. PubMed ID: 12972191
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Immune escape of gliomas.
    Walker PR; Dietrich PY
    Prog Brain Res; 2001; 132():685-98. PubMed ID: 11545028
    [No Abstract]   [Full Text] [Related]  

  • 73. Human tumor antigens recognized by T cells.
    Robbins PF; Kawakami Y
    Curr Opin Immunol; 1996 Oct; 8(5):628-36. PubMed ID: 8902387
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Probing T-cell Infiltration in Tumors.
    Cancer Discov; 2017 Jan; 7(1):5-6. PubMed ID: 27927681
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Generation of Phosphopeptide-Specific T Cell Lines as Tools for Melanoma Immunotherapy.
    Obeng RC; Ambakhutwala AL
    Methods Mol Biol; 2021; 2265():655-670. PubMed ID: 33704746
    [TBL] [Abstract][Full Text] [Related]  

  • 76. T cell responses in early-stage melanoma patients occur frequently and are not associated with humoral response.
    Pfirschke C; Gebhardt C; Zörnig I; Pritsch M; Eichmüller SB; Jäger D; Enk A; Beckhove P
    Cancer Immunol Immunother; 2015 Nov; 64(11):1369-81. PubMed ID: 26160687
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Immunotherapy: Adoptive cell therapy simplified.
    Kirk R
    Nat Rev Clin Oncol; 2013 Jul; 10(7):368. PubMed ID: 23689751
    [No Abstract]   [Full Text] [Related]  

  • 78. Immunogene therapy of human melanoma. Phase I/II clinical trial.
    Mackiewicz A; Kapcińska M; Wiznerowicz M; Malicki J; Nawrocki S; Nowak J; Murawa P; Sibilska E; Kowalczyk D; Lange A; Hawley RC; Rose-John S
    Adv Exp Med Biol; 1998; 451():557-60. PubMed ID: 10026927
    [No Abstract]   [Full Text] [Related]  

  • 79. Melanoma, immune surveillance, and immunotherapy.
    Ferrone S
    J Clin Invest; 1994 Apr; 93(4):1351-2. PubMed ID: 8163637
    [No Abstract]   [Full Text] [Related]  

  • 80. Identification of lung tumor antigens for cancer immunotherapy: immunological and molecular approaches.
    Henderson RA; Elliott M; Hopkins D; Fan L; Houghton R; Wang T
    Immunol Invest; 2000 May; 29(2):87-91. PubMed ID: 10854172
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.